AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study 28702451 — intervention group
Group type: EXPERIMENTAL
Intervention: Stabilization in supine (SIS)
Number of subjects: 56
Study 28702451 — intervention group
Group type: EXPERIMENTAL
Intervention: Combination of prone and supine (SIPS)
Number of subjects: 56
Study 28702451 — intervention group
Group type: COMPARATOR
Intervention: All groups (SIP, SIS, SIPS)
Number of subjects: 56
Study 24633458 — intervention group
Group type: EXPERIMENTAL
Intervention: Short-segmental fixation in situ with decompression and bone grafting
Number of subjects: 40
Study 24633458 — intervention group
Group type: COMPARATOR
Intervention: Long-segmental fixation with sufficient decompression and short-segmental fusion
Number of subjects: 40
Study 22085706 — intervention group
Group type: EXPERIMENTAL
Intervention: Internet-based weight loss interventions
Number of subjects: 352
Study 21062180 — intervention group
Group type: EXPERIMENTAL
Intervention: Transcranial magnetic stimulation (TMS)
Number of subjects: 20
Study 21062180 — intervention group
Group type: COMPARATOR
Intervention: Control group (no TMS)
Number of subjects: 20
Study 19025625 — intervention group
Group type: EXPERIMENTAL
Intervention: Dynamic arterial line pressure (DALP) based prescription of Qb (300-500 mL/min)
Number of subjects: 72
Study 16189075 — intervention group
Group type: EXPERIMENTAL
Intervention: Four-drug regimen (trimethoprim, sulfamethoxazole, doxycycline, and chloramphenicol)
Number of subjects: 180
Study 16189075 — intervention group
Group type: COMPARATOR
Intervention: Three-drug regimen (trimethoprim-sulfamethoxazole and doxycycline)
Number of subjects: 180
Study 16189075 — intervention group
Group type: EXPERIMENTAL
Intervention: Four-drug regimen
Number of subjects: 180
Study 16189075 — intervention group
Group type: COMPARATOR
Intervention: Three-drug regimen
Number of subjects: 180
Study 16189075 — intervention group
Group type: EXPERIMENTAL
Intervention: Duration of oral therapy
Number of subjects: 180
Study 12651645 — intervention group
Group type: EXPERIMENTAL
Intervention: Clonidine 5 micro g/kg
Number of subjects: 39
Study 12651645 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 39
Study 10651656 — intervention group
Group type: EXPERIMENTAL
Intervention: Pentasa 1 g sachet (unit dose, microgranules in a foil bag)
Number of subjects: 8
Study 10651656 — intervention group
Group type: COMPARATOR
Intervention: Pentasa 500 mg tablets (2 x 500 mg)
Number of subjects: 8
Study 7733059 — intervention group
Group type: EXPERIMENTAL
Intervention: Xylitol gum
Number of subjects: 60
Study 7733059 — intervention group
Group type: EXPERIMENTAL
Intervention: Sorbitol gum
Number of subjects: 60
Study 7733059 — intervention group
Group type: EXPERIMENTAL
Intervention: Xylitol-sorbitol mixture I (3:2)
Number of subjects: 60
Study 7733059 — intervention group
Group type: EXPERIMENTAL
Intervention: Xylitol-sorbitol mixture II (4:1)
Number of subjects: 60
Study 2254831 — intervention group
Group type: EXPERIMENTAL
Intervention: 0.04% CHX daily home marginal irrigation + 0.12% CHX professional irrigation
Number of subjects: 60
Study 2254831 — intervention group
Group type: EXPERIMENTAL
Intervention: Water daily home marginal irrigation + 0.12% CHX professional irrigation
Number of subjects: 60
Study 2254831 — intervention group
Group type: EXPERIMENTAL
Intervention: Water daily home marginal irrigation + water professional irrigation
Number of subjects: 60
Study 2254831 — intervention group
Group type: COMPARATOR
Intervention: Control group (no intervention)
Number of subjects: 60
Study 6104554 — intervention group
Group type: EXPERIMENTAL
Intervention: Atenolol (50 mg 3 times a day)
Number of subjects: 2
Study 6104554 — intervention group
Group type: EXPERIMENTAL
Intervention: Atenolol (100 mg twice daily)
Number of subjects: 2
Study 6104554 — intervention group
Group type: EXPERIMENTAL
Intervention: Propranolol (40 mg 3 times a day)
Number of subjects: 2
Study 6104554 — intervention group
Group type: EXPERIMENTAL
Intervention: Propranolol (80 mg 3 times a day)
Number of subjects: 2
Study 6104554 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 2
Study 30941887 — intervention group
Group type: EXPERIMENTAL
Intervention: Micronutrient powder (MNP) with nutrition education
Number of subjects: 0
Study 30941887 — intervention group
Group type: COMPARATOR
Intervention: Control group
Number of subjects: 0
Study 28319515 — intervention group
Group type: EXPERIMENTAL
Intervention: Smoking cessation program (counseling session, varenicline, educational pamphlet, fax referral to quitline)
Number of subjects: 296
Study 28319515 — intervention group
Group type: COMPARATOR
Intervention: Brief advice and self-referral to quitline
Number of subjects: 296
Study 26152568 — intervention group
Group type: EXPERIMENTAL
Intervention: Multifaceted feedback strategy (extensive monthly feedback reports, outreach visits, quality improvement team)
Number of subjects: 67237
Study 26152568 — intervention group
Group type: COMPARATOR
Intervention: Limited quarterly feedback reports (control group)
Number of subjects: 67237
Study 24187116 — intervention group
Group type: EXPERIMENTAL
Intervention: Postnatal nurse home visiting intervention (3 to 7 contacts between 3 and 12 weeks after birth)
Number of subjects: 549
Study 24187116 — intervention group
Group type: COMPARATOR
Intervention: Control group (no intervention)
Number of subjects: 549
Study 21890092 — intervention group
Group type: EXPERIMENTAL
Intervention: Nesiritide infusions
Number of subjects: 911
Study 21890092 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 911
Study 19218044 — intervention group
Group type: EXPERIMENTAL
Intervention: Megestrol acetate (MA), 40 mg twice daily for 2 months
Number of subjects: 22
Study 19218044 — intervention group
Group type: COMPARATOR
Intervention: Control group (no intervention)
Number of subjects: 22
Study 17374171 — intervention group
Group type: EXPERIMENTAL
Intervention: Cycling intervention (strengthening and cardiorespiratory endurance phases)
Number of subjects: 60
Study 17374171 — intervention group
Group type: COMPARATOR
Intervention: Control (no cycling)
Number of subjects: 60
Study 15310997 — intervention group
Group type: EXPERIMENTAL
Intervention: Dutasteride (5 mg per day for 6 to 10 weeks)
Number of subjects: 46
Study 15310997 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 46
Study 11764017 — intervention group
Group type: EXPERIMENTAL
Intervention: Alcohol
Number of subjects: 0
Study 11764017 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 0
Study 9663367 — intervention group
Group type: EXPERIMENTAL
Intervention: Venlafaxine (200 mg/d)
Number of subjects: 0
Study 9663367 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 0
Study 7875435 — intervention group
Group type: EXPERIMENTAL
Intervention: Enprostil (35 micrograms bid)
Number of subjects: 12
Study 7875435 — intervention group
Group type: EXPERIMENTAL
Intervention: Ranitidine (150 mg bid)
Number of subjects: 12
Study 7875435 — intervention group
Group type: COMPARATOR
Intervention: Comparison of Ranitidine and Enprostil
Number of subjects: 12
Study 2975684 — intervention group
Group type: EXPERIMENTAL
Intervention: Atenolol (50 mg once daily)
Number of subjects: 16
Study 2975684 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 16
Study 31481243 — intervention group
Group type: EXPERIMENTAL
Intervention: ACC/AHA criteria for hypertension diagnosis
Number of subjects: 370
Study 29097299 — intervention group
Group type: EXPERIMENTAL
Intervention: Low-dose aspirin (100mg daily)
Number of subjects: 1400
Study 27288347 — intervention group
Group type: EXPERIMENTAL
Intervention: LdP intervention
Number of subjects: 989
Study 27288347 — intervention group
Group type: COMPARATOR
Intervention: Control condition
Number of subjects: 989
Study 24074852 — intervention group
Group type: EXPERIMENTAL
Intervention: Adjective Rating Scale for Withdrawal (ARSW)
Number of subjects: 515
Study 24074852 — intervention group
Group type: EXPERIMENTAL
Intervention: Change from post-treatment through follow-up
Number of subjects: 515
Study 23044413 — intervention group
Group type: EXPERIMENTAL
Intervention: Moderate hypothermia (33 °C) for one hour (n=5)
Number of subjects: 14
Study 23044413 — intervention group
Group type: EXPERIMENTAL
Intervention: Moderate hypothermia (33 °C) for twenty-four hours (n=9)
Number of subjects: 14
Study 23044413 — intervention group
Group type: COMPARATOR
Intervention: Control (no hypothermia)
Number of subjects: 14
Study 21072246 — intervention group
Group type: EXPERIMENTAL
Intervention: Oseltamivir 75 mg orally twice daily plus zanamivir 10 mg by inhalation twice daily (OZ)
Number of subjects: 541
Study 21072246 — intervention group
Group type: COMPARATOR
Intervention: Oseltamivir plus inhaled placebo (O)
Number of subjects: 541
Study 21072246 — intervention group
Group type: COMPARATOR
Intervention: Zanamivir plus oral placebo (Z)
Number of subjects: 541
Study 18990048 — intervention group
Group type: EXPERIMENTAL
Intervention: Integrated acupuncture, tuina, and rehabilitation (physiotherapy, occupational therapy, and hydrotherapy) for 12 weeks (Group I)
Number of subjects: 116
Study 18990048 — intervention group
Group type: COMPARATOR
Intervention: Rehabilitation (physiotherapy, occupational therapy, and hydrotherapy) for 12 weeks followed by acupuncture and tuina for 12 weeks (Group II)
Number of subjects: 116
Study 18990048 — intervention group
Group type: EXPERIMENTAL
Intervention: Acupuncture treatment (both groups)
Number of subjects: 116
Study 17020559 — intervention group
Group type: EXPERIMENTAL
Intervention: Postconditioning (PCI with postconditioning)
Number of subjects: 94
Study 17020559 — intervention group
Group type: COMPARATOR
Intervention: IR group (PCI without postconditioning)
Number of subjects: 94
Study 12837190 — intervention group
Group type: EXPERIMENTAL
Intervention: ACD-CPR (cardio pump)
Number of subjects: 92
Study 12837190 — intervention group
Group type: COMPARATOR
Intervention: Standard CPR
Number of subjects: 92
Study 10739150 — intervention group
Group type: EXPERIMENTAL
Intervention: Transposition of the IDN into the intermuscular space
Number of subjects: 44
Study 10739150 — intervention group
Group type: COMPARATOR
Intervention: Standard resection operation
Number of subjects: 44
Study 8652909 — intervention group
Group type: EXPERIMENTAL
Intervention: Ondansetron combined with corticosteroids for acute cisplatin-induced emesis
Number of subjects: 0
Study 8652909 — intervention group
Group type: COMPARATOR
Intervention: Ondansetron
Number of subjects: 0
Study 8652909 — intervention group
Group type: COMPARATOR
Intervention: Not specified
Number of subjects: 0
Study 1308663 — intervention group
Group type: EXPERIMENTAL
Intervention: Fluconazole (100 mg/d)
Number of subjects: 169
Study 1308663 — intervention group
Group type: COMPARATOR
Intervention: Ketoconazole (200 mg/d)
Number of subjects: 169
Study 3931924 — intervention group
Group type: EXPERIMENTAL
Intervention: Bacillus subtilis (Enterogermina, Midy)
Number of subjects: 30
Study 3931924 — intervention group
Group type: COMPARATOR
Intervention: Placebo preparation
Number of subjects: 30
Study 31310160 — intervention group
Group type: EXPERIMENTAL
Intervention: Long-term methimazole therapy (60-120 months)
Number of subjects: 302
Study 31310160 — intervention group
Group type: COMPARATOR
Intervention: Conventional methimazole therapy (18-24 months)
Number of subjects: 302
Study 30156175 — intervention group
Group type: EXPERIMENTAL
Intervention: Military-approved uniforms
Number of subjects: 0
Study 30156175 — intervention group
Group type: COMPARATOR
Intervention: Hospital-provided scrubs
Number of subjects: 0
Study 26489045 — intervention group
Group type: EXPERIMENTAL
Intervention: rilpivirine/emtricitabine/tenofovir disoproxil fumarate (RPV/FTC/TDF)
Number of subjects: 786
Study 26489045 — intervention group
Group type: COMPARATOR
Intervention: efavirenz/emtricitabine/tenofovir disoproxil fumarate (EFV/FTC/TDF)
Number of subjects: 786
Study 25290556 — intervention group
Group type: EXPERIMENTAL
Intervention: augmented smartphone application
Number of subjects: 28
Study 25290556 — intervention group
Group type: COMPARATOR
Intervention: standard smartphone application
Number of subjects: 28
Study 22924638 — intervention group
Group type: EXPERIMENTAL
Intervention: FFR-guided PCI plus the best available medical therapy
Number of subjects: 1220
Study 22924638 — intervention group
Group type: COMPARATOR
Intervention: Best available medical therapy alone
Number of subjects: 1220
Study 22924638 — intervention group
Group type: COMPARATOR
Intervention: Registry patients (best available medical therapy)
Number of subjects: 1220
Study 19330342 — intervention group
Group type: EXPERIMENTAL
Intervention: ethinyl estradiol/cyproterone acetate (EE/CA)
Number of subjects: 48
Study 19330342 — intervention group
Group type: EXPERIMENTAL
Intervention: EE/CA-metformin
Number of subjects: 48
Study 19330342 — intervention group
Group type: EXPERIMENTAL
Intervention: metformin alone
Number of subjects: 48
Study 19330342 — intervention group
Group type: EXPERIMENTAL
Intervention: EE/CA-spironolactone
Number of subjects: 48
Study 19330342 — intervention group
Group type: EXPERIMENTAL
Intervention: EE/CA
Number of subjects: 48
Study 19330342 — intervention group
Group type: COMPARATOR
Intervention: Control group not specified
Number of subjects: 48
Study 17355402 — intervention group
Group type: EXPERIMENTAL
Intervention: Nurse home visiting programs for pregnant women and parents of young children
Number of subjects: 0
Study 15737251 — intervention group
Group type: EXPERIMENTAL
Intervention: Quetiapine
Number of subjects: 45
Study 15737251 — intervention group
Group type: COMPARATOR
Intervention: Haloperidol
Number of subjects: 45
Study 12206949 — intervention group
Group type: EXPERIMENTAL
Intervention: 1.5-4 months post-ACL reconstruction
Number of subjects: 96
Study 12206949 — intervention group
Group type: EXPERIMENTAL
Intervention: 6-7 months post-ACL reconstruction
Number of subjects: 96
Study 12206949 — intervention group
Group type: EXPERIMENTAL
Intervention: 12-15 months post-ACL reconstruction
Number of subjects: 96
Study 12206949 — intervention group
Group type: COMPARATOR
Intervention: Control group (no history of lower extremity pathology/injury)
Number of subjects: 96
Study 9689432 — intervention group
Group type: EXPERIMENTAL
Intervention: Nutrient-mixture (Aminoleban EN) 100 g/day for 2 to 6 weeks
Number of subjects: 18
Study 9689432 — intervention group
Group type: COMPARATOR
Intervention: Control (no nutrient-mixture)
Number of subjects: 18
Study 9689432 — intervention group
Group type: EXPERIMENTAL
Intervention: Nutrient-mixture (Aminoleban EN)
Number of subjects: 18
Study 7806469 — intervention group
Group type: EXPERIMENTAL
Intervention: Cold Water immersion (0 degree C) of the right hand
Number of subjects: 15
Study 7806469 — intervention group
Group type: EXPERIMENTAL
Intervention: Cold Water immersion (0 degree C) of the left hand
Number of subjects: 15
Study 7806469 — intervention group
Group type: COMPARATOR
Intervention: Warm Water immersion (control)
Number of subjects: 15
Study 2777728 — intervention group
Group type: EXPERIMENTAL
Intervention: Intravenous gentamicin and 12 g/day piperacillin
Number of subjects: 127
Study 2777728 — intervention group
Group type: EXPERIMENTAL
Intervention: Intravenous gentamicin and 8 g/day piperacillin
Number of subjects: 127
Study 2777728 — intervention group
Group type: COMPARATOR
Intervention: Intravenous gentamicin and piperacillin (both doses)
Number of subjects: 127
Study 2777728 — intervention group
Group type: EXPERIMENTAL
Intervention: Further antibiotics added to unresponsive patients
Number of subjects: 127
Study 29762196 — intervention group
Group type: EXPERIMENTAL
Intervention: High-Intensity Interval Training (HIIT)
Number of subjects: 32
Study 29762196 — intervention group
Group type: EXPERIMENTAL
Intervention: Continuous Aerobic (CA)
Number of subjects: 32
Study 29762196 — intervention group
Group type: COMPARATOR
Intervention: Delayed Control
Number of subjects: 32
Study 28814835 — intervention group
Group type: EXPERIMENTAL
Intervention: Generic formulation of atorvastatin (Atorva®) 20 mg once daily
Number of subjects: 376
Study 28814835 — intervention group
Group type: COMPARATOR
Intervention: Reference formulation of atorvastatin (Lipitor®) 20 mg once daily
Number of subjects: 376
Study 25712802 — intervention group
Group type: EXPERIMENTAL
Intervention: 1-month BCI-supported MI training (BCI group, n=14)
Number of subjects: 28
Study 25712802 — intervention group
Group type: COMPARATOR
Intervention: 1-month MI training without BCI support (control group; n=14)
Number of subjects: 28
Study 23155122 — intervention group
Group type: EXPERIMENTAL
Intervention: Nicotine nasal spray
Number of subjects: 47
Study 20185409 — intervention group
Group type: EXPERIMENTAL
Intervention: 40-microg Engerix-B
Number of subjects: 87
Study 20185409 — intervention group
Group type: COMPARATOR
Intervention: 80-microg Engerix-B
Number of subjects: 87
Study 20185409 — intervention group
Group type: EXPERIMENTAL
Intervention: Seroconversion (both groups)
Number of subjects: 87
Study 18823024 — intervention group
Group type: EXPERIMENTAL
Intervention: Uracil/tegafur (UFT) and gemcitabine (GEM) together (GU)
Number of subjects: 100
Study 18823024 — intervention group
Group type: COMPARATOR
Intervention: Gemcitabine (G) alone
Number of subjects: 100
Study 16215367 — intervention group
Group type: COMPARATOR
Intervention: Control groups from recent randomized controlled trials on severe sepsis
Number of subjects: 70000
Study 12820466 — intervention group
Group type: EXPERIMENTAL
Intervention: Intraarterial continuous infusion of cisplatin (CDDP), 24 mg/m2/day
Number of subjects: 123
Study 12820466 — intervention group
Group type: COMPARATOR
Intervention: Bolus of cisplatin (CDDP), 24 mg/m2/day
Number of subjects: 123
Study 12820466 — intervention group
Group type: EXPERIMENTAL
Intervention: Both arms received i.v. escalating doses of fluorouracil
Number of subjects: 123
Study 11113295 — intervention group
Group type: EXPERIMENTAL
Intervention: Placebo and hidden naloxone
Number of subjects: 60
Study 11113295 — intervention group
Group type: COMPARATOR
Intervention: Hidden naloxone only
Number of subjects: 60
Study 11113295 — intervention group
Group type: EXPERIMENTAL
Intervention: Placebo and hidden saline
Number of subjects: 60
Study 11113295 — intervention group
Group type: COMPARATOR
Intervention: Hidden saline only
Number of subjects: 60
Study 8839635 — intervention group
Group type: EXPERIMENTAL
Intervention: New delayed-release formulation of UDCA
Number of subjects: 0
Study 8839635 — intervention group
Group type: COMPARATOR
Intervention: Traditional pH-dependent sequential release formulation of UDCA
Number of subjects: 0
Study 1948791 — intervention group
Group type: EXPERIMENTAL
Intervention: Inhaled PGE2 (100 micrograms)
Number of subjects: 9
Study 1948791 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 9
Study 6421010 — intervention group
Group type: EXPERIMENTAL
Intervention: 1 mg buccal nitroglycerin
Number of subjects: 60
Study 6421010 — intervention group
Group type: EXPERIMENTAL
Intervention: 2.5 mg buccal nitroglycerin
Number of subjects: 60
Study 6421010 — intervention group
Group type: EXPERIMENTAL
Intervention: 5.0 mg buccal nitroglycerin
Number of subjects: 60
Study 6421010 — intervention group
Group type: COMPARATOR
Intervention: 0.8 mg sublingual nitroglycerin
Number of subjects: 60
Study 31069557 — intervention group
Group type: EXPERIMENTAL
Intervention: Robot-assisted ventral mesh rectopexy (RVMR)
Number of subjects: 30
Study 31069557 — intervention group
Group type: COMPARATOR
Intervention: Laparoscopic ventral mesh rectopexy (LVMR)
Number of subjects: 30
Study 31069557 — intervention group
Group type: COMPARATOR
Intervention: RVMR compared to LVMR
Number of subjects: 30
Study 31069557 — intervention group
Group type: EXPERIMENTAL
Intervention: Both RVMR and LVMR
Number of subjects: 30
Study 28196503 — intervention group
Group type: EXPERIMENTAL
Intervention: G-MISS questionnaire
Number of subjects: 2055
Study 28196503 — intervention group
Group type: COMPARATOR
Intervention: Medical or surgical specialties
Number of subjects: 2055
Study 28196503 — intervention group
Group type: COMPARATOR
Intervention: Consultation shorter than 5 minutes
Number of subjects: 2055
Study 27040324 — intervention group
Group type: EXPERIMENTAL
Intervention: Transcatheter aortic-valve replacement (TAVR)
Number of subjects: 2032
Study 27040324 — intervention group
Group type: COMPARATOR
Intervention: Surgical aortic-valve replacement
Number of subjects: 2032
Study 27040324 — intervention group
Group type: EXPERIMENTAL
Intervention: Transcatheter aortic-valve replacement (TAVR) in transfemoral-access cohort
Number of subjects: 2032
Study 27040324 — intervention group
Group type: COMPARATOR
Intervention: Surgical aortic-valve replacement in transfemoral-access cohort
Number of subjects: 2032
Study 25095775 — intervention group
Group type: EXPERIMENTAL
Intervention: Vestibulopathy with visual vertigo (VV)
Number of subjects: 28
Study 25095775 — intervention group
Group type: COMPARATOR
Intervention: Healthy controls
Number of subjects: 28
Study 22822451 — intervention group
Group type: EXPERIMENTAL
Intervention: NuFit active blend (2.25 g leucine and 30 mg pyridoxine)
Number of subjects: 20
Study 19535190 — intervention group
Group type: EXPERIMENTAL
Intervention: Nicorandil, 15 mg/d
Number of subjects: 129
Study 19535190 — intervention group
Group type: COMPARATOR
Intervention: Control (no nicorandil)
Number of subjects: 129
Study 16636341 — intervention group
Group type: EXPERIMENTAL
Intervention: sorafenib (400 mg twice daily)
Number of subjects: 202
Study 16636341 — intervention group
Group type: COMPARATOR
Intervention: placebo
Number of subjects: 202
Study 16636341 — intervention group
Group type: EXPERIMENTAL
Intervention: entire renal cell carcinoma population
Number of subjects: 202
Study 14673047 — intervention group
Group type: EXPERIMENTAL
Intervention: Surgery plus chemotherapy (cisplatin 80 mg/m2 x 1 day and fluorouracil 800 mg/m2 x 5 days)
Number of subjects: 242
Study 14673047 — intervention group
Group type: COMPARATOR
Intervention: Surgery alone
Number of subjects: 242
Study 14673047 — intervention group
Group type: EXPERIMENTAL
Intervention: Surgery plus chemotherapy
Number of subjects: 242
Study 11196553 — intervention group
Group type: EXPERIMENTAL
Intervention: Flecainide
Number of subjects: 22
Study 11196553 — intervention group
Group type: EXPERIMENTAL
Intervention: Disopyramide
Number of subjects: 22
Study 11196553 — intervention group
Group type: EXPERIMENTAL
Intervention: Mexiletine
Number of subjects: 22
Study 11196553 — intervention group
Group type: COMPARATOR
Intervention: Control group (no intervention)
Number of subjects: 22
Study 8818438 — intervention group
Group type: EXPERIMENTAL
Intervention: Two-legged knee extensor training (n = 7) for 15 min at 65-75% of VO2 max (about 4 kg working muscle)
Number of subjects: 14
Study 8818438 — intervention group
Group type: EXPERIMENTAL
Intervention: One-legged dynamic knee extensor training (n = 7) for 15 min at 35% of VO2 max (about 2 kg working muscle)
Number of subjects: 14
Study 8818438 — intervention group
Group type: COMPARATOR
Intervention: Control group (n = 7)
Number of subjects: 14
Study 1610576 — intervention group
Group type: EXPERIMENTAL
Intervention: Methohexital anesthesia (0.5 to 1.0 mg/kg) with atropine premedication
Number of subjects: 49
Study 1610576 — intervention group
Group type: EXPERIMENTAL
Intervention: Methohexital anesthesia (0.5 to 1.0 mg/kg)
Number of subjects: 49